News | Cardiac Diagnostics | December 14, 2015

Mount Sinai Initiates Clinical Study of MyoVista Heart Screening Device

Clinical study will evaluate new technology from Heart Test Laboratories as possible low-cost screening tool for early heart disease

Heart Test Laboratories, HTL, MyoVista Heart Screening Device, clinical study, Mount Sinai

December 14, 2015 — Heart Test Laboratories Inc. (HTL) announced the commencement of a clinical study, initiated by Mount Sinai Medical Center, New York, examining the MyoVista heart screening device. The clinical study is designed to further evaluate the MyoVista, which incorporates HTL’s patented technology for the early detection of heart disease. The study will assess the MyoVista indications for the identification of coronary arterial disease (CAD) as compared to computed tomographic coronary angiography (CTA) and myocardial dysfunction in patients without CAD as compared to echocardiography.

The lead investigator is Partho Sengupta, M.D., the director of cardiac ultrasound research and core lab, and an associate professor of medicine in cardiology at Mount Sinai’s Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josée and Henry R. Kravis Center for Cardiovascular Health. The clinical study is expected to enroll 200 patients and take between 12-24 months to complete.

Heart disease is the leading cause of death in the U.S., being responsible for 1 in every 4 deaths (approx. 600,000 per year U.S.). It is the leading cause of deaths worldwide, more than all cancers combined, and is the largest spend area in healthcare. Heart disease is known as the silent killer because most affected people do not know they have it (i.e. they are asymptomatic); more than half of patients find out through an adverse event (angina, heart attack or even death).

The “diagnostic gap” in heart disease today is non-invasive, low-cost screening to identify asymptomatic patients before an adverse event occurs. Existing electrocardiography (ECG) technology is generally not considered effective for use on asymptomatic patients. The U.S. Preventive Services Taskforce and other healthcare bodies around the world recommend against screening with resting or exercise ECG for the prediction of coronary heart disease (CHD) events in asymptomatic adults at low risk for CHD events.

The MyoVista provides two tests in one and is easy for physicians to use. By using standard 12-lead resting ECG protocols, the device provides an ECG test incorporating interpretive analysis, as well as easy-to-understand proprietary informatics that assist a physician in identifying heart disease at an early stage.

HTL believes the MyoVista will provide the opportunity for effective, low-cost testing for heart disease in primary care. This would enable physicians to have a valuable additional tool to assist in the process of determining referrals to a cardiologist.

It has a 15.6-inch high resolution touch screen and incorporates user features and functionality commonly associated with a tablet device which make it intuitive and easy to use, thereby reducing training time. Its proprietary informatics provide information to physicians that suggest ischemic and certain types of structural heart abnormalities. The MyoVista is ideally suited for use in both primary care and hospital environments.

For more information: www.hearttestlabs.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging| August 18, 2017
August 18, 2017 — The American Society of...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
AUM Cardiovascular Receives FDA Approval for CADence ECG Device
Technology | ECG| August 08, 2017
AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a...
Overlay Init